Papillary Renal Cell Carcinoma
Oncology·MeSH: Papillary renal cell carcinoma, sporadic
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| savolitinib | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Papillary Renal Cell Carcinoma?
BioSniper tracks 1 drug in development for Papillary Renal Cell Carcinoma across 1 company.
How many clinical trials target Papillary Renal Cell Carcinoma?
There are 4 clinical trials targeting Papillary Renal Cell Carcinoma tracked by BioSniper.
What is the prevalence of Papillary Renal Cell Carcinoma?
The estimated prevalence of Papillary Renal Cell Carcinoma is approximately 48.0 per 100,000 population.
Deep-dive into Papillary Renal Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis